At a glance
ClinicalIndex Comparison RecordN/ACompleted· 183 enrolled
Drug / intervention
Xoft eBxdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Post-market Multi-Center Retrospective-Prospective Study to Assess Long-term Clinical Outcomes of Non-melanoma Skin Cancer Patients Treated With eBx
In Brief
An observational study evaluating Xoft eBx for Non-melanoma Skin Cancer. Completed, enrolled 183 participants across 2 sites.
Detailed Summary
The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-melanoma Skin Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionJul 2022
Study CompletionOct 2022
TodayJul 2026
First PostedFeb 25, 2022
Enrollment StartMar 9, 2022
Primary CompletionJul 18, 2022
Study CompletionOct 13, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.4 years ago
Interventions
Xoft eBxdevice
The Xoft Axxent Electronic Brachytherapy (eBx) System allows for the administration of high dose rate brachytherapy treatments using an electronic source